Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Very comprehensive write up from Doc & Wigster. To be fair to Reddit I was reading live and detailed updates throughout the AGM.
Hi Doc83,
Yes perhaps Phillip Monk isn’t a natural presentation persona when dealing with the amalgamation of scientific and financial issues, no doubt more comfortable in just a scientific arena.
I must admit the remuneration and salary questions being fired in quite incessantly made me winch at times :) still fair play to the questioning no complaints from me :)
Blimey has no one learnt their lesson! People really are reading what they want to hear from the AGM update and clearly overlooking some clear signals.
The previous share price highs where reflective of a drug company on the cusp of commercialisation.
Whilst making it onto an open platform trip will be great news I don’t expect a huge uplift.
There are a lot of pain points on the way up here as we have a significant amount of holders in the red.
People need to start thinking in timeframes of 6months chunks rather than the next two months will be great.
The reality is little will change in 2months. In 6months time we may be in the middle of a platform trial.
In 12months time we may be talking results of that trial in 18 months time we may be talking commercialisation.
These are the real inflection points. 2months time we’ll be trading the same range as today.
*share the AGM post on other boards
Tommy - that’s great to hear, and I forgot to say that all were welcome to post on other boards.
I’ll admit, I thought he seemed slightly stand-offish. I can’t recall which question (possibly where we were pushing for more info on ACTIV and when we might get the data/could they do more etc) and he slightly snapped. All my own opinion. He just didn’t seem as much of a people person as the others, but I suppose he is a scientist and not a speaker.
In his defence, I did see him immediately after the Q&A proactively seek out one investor to answer his question in more detail on a one to one, so credit to him for that!
And thinking back, Iain Buchanan looked distinctly unimpressed when we were questioning him on how he had worked out such significant pay rises for everyone!
Just a note to say those on the board that can’t be mentioned because some people here like to ridicule them.
They made a specific point in their forum of pointing out how good Doc83 and Wigster thorough update of the AGM was. I think the comment was something like “There’s a great AGM update on LSE”
Don’t believe everything you read in here, they’re a really nice group who openly discuss issues and have some great research.
Hi Doc83
Thinking back now, perhaps he was quite influential amongst the BoD, there appeared to be on several occasions where the other board’s members turned to him, hard to say whether it was for tacit approval or perhaps for him to join in to reaffirm answers with extra information.
Of course I may be on a completely different wavelength to your thoughts, as for me the meeting passed by so quickly and trying to take recap notes and listen was a real task most of the time.
By the way both yours and Wigsters recap notes of the AGM were excellent and your hard work deserved the appreciation you received on this board, shame we didn’t get to speak to each other.
ATB.
Hi Jint, a slightly unusual question at first glance perhaps, but what did you think of Phillip Monk?
SBT..
The Board will have seen their personal fortunes devasted by the SPRINTER results..
They all have a significant shareholding here.... So I imagine they are as keen as us
to see a commercial endpoint here...!
Hi Jint
Thanks for taking the time to reply and your insight. I think RM and the team are ambitious but from interviews I've seen they all seem polite, understated and very British making it hard to determine their drive and energy.
Hopefully there are still exciting times ahead for Synairgen.
ATB
SBT
IMHO... The most important short term game-changer could be our
Long Covid results..... Every newspaper today is reporting huge spikes
in cases.... Moreover, hospital admissions... So at the height of Summer
this will send shock waves through those planning for this Winter...
Personally I think there are many potential options for SNG001 to
be playing a major role in treating Covid before next Summer!
Our safety record has never been in question, from the hints RM
gave about a Platform trial, I think we have pretty much been accepted,
if there is a crisis this winter ( or even before at this rate) things
could escalate for SNG001 very quickly....This was acknowledged at
the AGM...ATB!
Remember when it comes to how long a trial takes and I’m sure some people will be emphasising a year plus. There’s such a thing as interim analysis and these trials kick you off without a second blink if your drug is a dud. So if we’re on a PT and haven’t been kicked off next summer then as the BOD said at the AGM. They will be in a completely different place to where they find themselves now and so will the share price
Patience and patients.
The next few months should be pretty positive for us.
I’m sure the usual suspects will push the running out of money, dilution and a buyout for 30p nonsense way beyond credibility but ignore that.
We should get a peer review soon
We will get positive results from Activ2 otherwise we wouldn’t have progressed.
It seems clear. From RM’s comments “We’re top of the pile for data and results for a PT” and his “Happy to say strongly envisage treating patients this winter” that we will be on a PT for COVID-19
We may even be part of a JV multi virus trial
Long Covid data still to come
We can be confident our drug works because in a third of the patients “The Responder group” it showed a 70% improvement. It was a statistically significant p value and those patients were receiving SOC just like all Sprinter patients.
So we have nothing to fear from SOC. it’s all about patient numbers on the trial.
Once we’re in a trial, with all the above and progressing, the share price will move positively.
Patience is all you need
Hi jint
Many thanks for the reply! ATB!
Hi Manifesto,
I don’t recall that question being raised, they were as shocked as us with the unexpected results as was
intimated at the AGM by the BoD.
My personal opinion (not a mistake) is they needed time to gather their thoughts (rather than rush out a statement) and to fully digest the shortfalls in the Sprinter trial results. Hence the announcement of the deep dive which I was content to wait for rather than having an early statement or Q&A session with no real substance and leaving us still scratching our heads in frustration.
Having spoke to RM after the AGM with a couple of others (he came over to us), I cannot fault his visible commitment and determination to enable the successful commercialisation of SNG001.
He came across honest and genuine, I’m very content to have him as our CEO.
ATB.
Thanks jint for your thoughts on the AGM !
I am curious, did anyone ask RM why he did not address shareholders after the SPRINTER results?
Many on here like me thought that as our CEO he should have done a Q&A or at least released a statement
but there was total silence..... Do yo feel he thought that was a mistake and that is why
they were open to questions at the AGM? Thanks!
Good morning soonbetime,
I too mainly observe on here but thought it worth replying to your post.
I attended the AGM and from my observations the BoD certainly gave a robust impression that they are driven to the successful commercialisation of SNG001 and not of one wanting to remain in the backwaters of research & development.
As an aside, they were extremely approachable and took the time to talk to individual investors prior (in welcoming) and more importantly after the AGM, from my perspective I came away invigorated that this company will succeed in the commercialisation of SNG001.
ATB
You, me and a hundred others.
But I remain confident my loss is a paper loss and the drug has tremendous upside. Even if some extra funding / dilution is required somewhere down the line, compared to the potential value for a variant proof, multi virus drug, we will all still be very happy with our return.
A lot will depend on where we are in June next year, how well the trial is going and what impact that has had on the share price. The more patients we recruit in a PT the better position we are in as a company to a partner. If the drug is working as many of us know it does, if we have the right patient numbers we will prove it. I think many Big Pharma’s recognise that.
TommyD_19,
Thanks for your perspective on the P3 trial - which, oddly, I’ve recommended - because half of me is inclined to give the co. the benefit of the doubt.
The other half is annoyed, firstly with myself for failing to spot the change in Sprinter protocol (I’d have invested much less) and secondly with the co. for overconfidence in going it alone and also going too multi-country.
I am torn between my admiration for Prof Holgate ( with whom I had dealings many years ago) and my distrust of Richard Marsden (the beard was when it began…).
So I guess I’ll watch what develops, with much reduced expectations, but fingers crossed.
Thanks for the report gents.
In my previous career I used to go to quite a few company presentations. They are always jolly compelling. But from what you say, it sounds to me as though it’s worth hanging on here to see if something can be salvaged .
Thanks for the brilliant feedback from the AGM.
I think this message board will be a lot quieter over the next few months as a few long term holders put this share mentally in the bottom drawer now the AGM is out of the way. This share and message board had probably become an unhealthy obsession for many over the last 2 plus years.
From a personal point of view the AGM went as I expected with no new startling information but some hope for the future. I’m still not sure if Synairgen management are driven to commercialise the product or comfy as a university spin research company earning very good salaries. Polygon may not ultimately act in small holders interests but at least they will hold the management to account in the short term. Time will tell and I hope I’m wrong but I don’t see the share price above £1 in the next 18 months.
I’ve mainly been a silent observer but thanks to all (nearly all) who have contributed on this board over the last couple of years. It feels like we were so near but so far.
I’m going to maintain my holding for the long term but will probably only check in quarterly.
Good luck with all your investments.
Cheers
SBT
Thanks Doc and Wigster for your time and effort. Above and beyond but shows that there remains a sense of community on here which is still valuable. From the crack in the bottom draw there appears to be a flickering light at the end of a tunnel. Long way back for many of us but you have managed to offer some form of optimism, that would otherwise be absent, by taking the time to share your experience. Humanity still needs this to be good, one mutation away from disaster. GLA.
That’s great to hear Wigster and I hope he gets the answers he seeks.
My perspective on P3 for what it’s worth:
P2 no one had steroids so I’m not sure how the company could have known the impact and extent of their use would impact P3
SOC improves dramatically and I’m not just talking about Dexamethesone. A wide and diverse range of drugs became available like Remdesivir and numerous others now listed in clinical guidance.
Vaccines became available and widely used
The virus mutated and it’s severity changed.
Autoantibodies play some critical role in deciding which patients may become sicker than others.
We have some of the worlds leading respiratory scientist and I simply don’t accept that there was or should have been some obvious knowledge they missed that indicated their drug wouldn’t work.
In fact the drug has been shown to work in multiple
Trials if targeted at the right group of patients and discovering that so called responder group has been a learning curve